The Day Amarin Investors Have Waited For

After yet another FDA delay regarding Vascepa's NCE status, Amarin investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline . In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with the Fool's premium research report on this biotech. Click here now to keep reading.

The article The Day Amarin Investors Have Waited For originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.